Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
APRE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.86
vs -2.40
Q4.23
N/A
-0.92
vs -0.92
Q1.24
N/A
-0.67
vs -1.34
Q2.24
N/A
-0.58
vs -0.87
Q3.24
N/A
-0.64
vs -0.86
Q4.24
N/A
-0.49
vs -0.92
Q1.25
N/A
-0.66
vs -0.67
Q2.25
N/A
-0.53
vs -0.58
Q3.25
N/A
-0.34
vs -0.64
Q4.25
N/A
-0.34
vs -0.49
Sales Growth
YoY
Current
Estimates
Q3.23
NA
319.5K vs NA
Q4.23
NA
14.1K vs NA
Q1.24
NA
380.6K vs NA
Q2.24
+125%
561.6K vs 249.7K
Q3.24
+11%
354.6K vs 319.5K
Q4.24
+1362%
205.8K vs 14.1K
Q1.25
-100%
NA vs 380.6K
Q2.25
-79%
118.1K vs 561.6K
Q3.25
-65%
124.9K vs 354.6K
Q4.25
-36%
132.1K vs 205.8K
Return on Equity
QoQ
Q1.23
-16%
-0.16
vs -4.32
Q2.23
-14%
-0.14
vs -0.16
Q3.23
-16%
-0.16
vs -0.14
Q4.23
-19%
-0.19
vs -0.16
Q1.24
-9%
-0.09
vs -0.19
Q2.24
-13%
-0.13
vs -0.09
Q3.24
-16%
-0.16
vs -0.13
Q4.24
-14%
-0.14
vs -0.16
Q1.25
-25%
-0.25
vs -0.14
Q2.25
-23%
-0.23
vs -0.25
Institutionnal Ownership
QoQ
Q4.22
27
27
vs 26
4%
Q1.23
18
18
vs 27
-33%
Q2.23
19
19
vs 18
6%
Q3.23
22
22
vs 19
16%
Q4.23
21
21
vs 22
-5%
Q1.24
24
24
vs 21
14%
Q2.24
28
28
vs 24
17%
Q3.24
22
22
vs 28
-21%
Q4.24
26
26
vs 22
18%
Q1.25
26
26
vs 26
NA
Forecast
662%2026-Revenue
-153%2026-EPS
105%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
Loop Capital Markets
initialisePrevious: Not converted
2023-03-10
Now: Buy
Citigroup
initialisePrevious: Not converted
2023-03-10
Now: Buy
RBC Capital
initialisePrevious: Not converted
2023-03-10
Now: Outperform
Cowen & Co.
initialisePrevious: Not converted
2023-03-10
Now: Market Perform
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
-0.04 ( -2.37%)
Relative Strenght
18
Volume Buzz
-21%
Earning Acce
No
Dist 52w H.
67%Relative Strength
APRE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
